Efficacy of anti-tumor necrosis factor therapy on endometriosis in an experimental rat model

Ebru Zulfikaroglu, Ebru Zülfikaroğlu, Sevtap Kılıç, Sevtap Kılıc, Mine Islimye, Murat Aydin, Murat Aydın, Sema Zergeroğlu, Sema Zergeroglu, Sertac Batioglu, Sertaç Batıoğlu
Archives of gynecology and obstetrics · 2010 · vol. 283(4) , pp. 799–804 · doi:10.1007/s00404-010-1434-0 · PMID:20333392 · W2063321199
article OA: closed CC0 ⤵ 28 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Etanercept treatment significantly reduced endometriosis implant volume and inflammatory markers in a rat model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The paper studied whether anti–tumor necrosis factor therapy (etanercept) reduces endometriosis development in a randomized, placebo-controlled, blinded Wistar rat model after peritoneal implantation of endometrial tissue. Twenty-two rats received either weekly subcutaneous etanercept (0.4 mg/kg) or saline vehicle, and after four weeks the authors remeasured implant spherical volume and assessed VEGF, IL-6, and TNF-α levels in blood and peritoneal fluid. Etanercept-treated rats showed significantly lower implant spherical volume than controls and significant differences in cytokine and VEGF levels between peritoneal fluid and serum within the etanercept group. A key caveat explicitly implied by the design is the short four-week experimental timeframe and use of an animal model, without confirmation in longer or human studies; This paper is centrally about endometriosis — it tests etanercept efficacy for reducing experimentally induced endometriosis in rats.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Endometrium Immunoglobulin G Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Animals Disease Models, Animal Endometriosis Endometrium Etanercept Female Immunoglobulin G Immunoglobulin G Interleukin-6 Interleukin-6 Random Allocation Rats Rats, Wistar Receptors, Tumor Necrosis Factor Transplantation, Autologous

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (28)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:12.951333+00:00
License: CC0 · commercial use OK